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Abstract
Background: Circulating bone marrow-derived endothelial progenitor cells (EPCs) have been reported to
participate in tumor angiogenesis and growth; however, the role of circulating EPCs in tumor progression is
controversial. The role of circulating EPCs in ovarian cancer progression and angiogenesis has not yet been
investigated.
Methods: The number of circulating EPCs in the peripheral blood in 25 healthy volunteers and 42 patients with
ovarian cancer was determined by flow cytometry. EPCs were defined by co-expression of CD34 and vascular
endothelial growth factor receptor 2 (VEGFR2). In addition, we determined CD34 and VEGFR2 mRNA levels by real-
time reverse transcription-polymerase chain reaction. Plasma levels of vascular endothelial growth factor (VEGF) and
matrix metalloproteinase-9 (MMP-9) were determined by enzyme-linked immunosorbent assay.
Results: Circulating levels of EPCs were significantly increased in ovarian cancer patients, correlating with tumor
stage and residual tumor size. Higher levels of EPCs were detected in patients with stage III and IV ovarian cancer
than in patients with stage I and II disease. After excision of the tumor, EPCs levels rapidly declined. Residual tumor
size greater than 2 cm was associated with significantly higher levels of EPCs. In addition, high circulating EPCs
correlated with poor overall survival. Pretreatment CD34 mRNA levels were not significantly increased in ovarian
cancer patients compared with healthy controls; however, VEGFR2 expression was increased, and plasma levels of
VEGF and MMP-9 were also elevated.
Conclusions: Our results demonstrate the clinical relevance of circulating EPCs in ovarian cancer. EPCs may be a
potential biomarker to monitor ovarian cancer progression and angiogenesis and treatment response.
Introduction
Ovarian cancer is one of the most aggressive gynecologi-
cal malignancies, and its high mortality is most often a
direct result of delayed diagnosis. Only 25% of ovarian
cancers are diagnosed while the malignancy is still con-
fined to the ovary, and the cure rate in these patients can
reach 90%. The remaining 75% of ovarian tumors have
spread beyond the ovary by the time of diagnosis, and the
cure rate for these patients is lower than 20% [1].
With the advent of molecular-targeted therapies, treat-
ment for ovarian cancer is now moving beyond conven-
tional chemotherapy. Inhibition of the specific cytokines
essential for tumor vascularization is one such a therapy
[2]; thus, anti-angiogenesis therapy has become a new
strategy for ovarian cancer treatment. No proven bio-
markers of tumor angiogenesis have been fully charac-
terized; however, tumor microvascular density is used to
predict tumor metastasis, recurrence, and prognosis.
Determining microvascular density is a highly invasive
procedure, and its association with the clinical outcome
in ovarian cancer is uncertain [3,4]. For that reason, the
development of noninvasive biomarkers would be useful
to evaluate tumor angiogenesis and growth as well as
the efficacy of antiangiogenic drugs in ovarian cancer.
Recent studies using various animal models of cancer
have suggested a role for EPCs in tumor angiogenesis
and growth [5,6]. EPCs are present in the peripheral
blood; in response to certain signals or cytokines, their
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any medium, provided the original work is properly cited.levels are elevated and they are recruited into the neo-
vascular bed of the tumor [7]. Emerging evidence sug-
gests that changes in EPC levels may predict the efficacy
of anticancer drug combinations that include antiangio-
genic agents [8]. Although these data suggest a relation-
ship between EPCs and tumor angiogenesis, the exact
role of these cells in the pathogenesis of ovarian cancer
has not been completely elucidated.
The aim of this study was to determine the correlation
between EPC levels and disease progression and angio-
g e n e s i si no v a r i a nc a n c e r .T ot h a te n d ,w eq u a n t i f i e d
circulating EPCs from the peripheral blood of ovarian
cancer patients by flow cytometry, before and after can-
cer treatment. In addition, we used real-time quantita-
tive reverse transcription polymerase chain reaction
(RT-PCR) to evaluate mRNA levels of EPC-specific mar-
kers CD34 and vascular endothelial growth factor recep-
tor 2 (VEGFR2) in the peripheral blood of ovarian
cancer patients. Plasma protein levels of vascular
endothelial growth factor (VEGF) and matrix metallo-
peptidase-9 (MMP-9) were also determined.
Materials and methods
Patients
This study was approved by the local ethics committee,
and informed consent was obtained from all study parti-
cipants. Forty-two patients (median age, 43 years old;
age range, 21-59 years old) with histologically proven
ovarian cancer, including serous cancer (n = 23), muci-
nous cancer (n = 13), and endometrioid cancer (n = 6),
were included along with a control group of healthy
women (n = 25, age range, 18-35 years old). Tumors
were classified according to the 1987 staging criteria
recommended by the Federation of Obstetrics and
Gynecology (FIGO). Of these patients, 30 patients
underwent surgery for their malignancy, and 12 patients
were treated with chemotherapy. These patients had no
additional malignant, inflammatory, or ischemic disease,
wounds, or ulcers that could influence the number of
circulating EPCs. Peripheral blood samples of these
patients were collected prior to treatment. All patients
in this study received regular follow-up for 18 to 24
months (median follow-up, 20.2 months) after discharge.
During this period, patients underwent physical exami-
nations and related laboratory tests or imaging examina-
tions once every 1 to 3 months. Blood samples were
collected at 1 month after chemotherapy or surgery.
Biological Samples and Flow Cytometric Analysis
Analysis was based on the expression of surface markers
CD34 and VEGFR2 on cells in the mononuclear gate
where EPCs are commonly found. CD34
+ and VEGFR2
+
are commonly used as markers for EPCs [9-11]. Periph-
eral blood was collected by venipuncture using
ethylenediaminetetraacetic acid (EDTA) as an anticoagu-
lant. Then, 100 μL whole blood was labeled with phy-
coerythrin (PE)-conjugated anti-human VEGFR2 and
fluorescein isothiocyanate (FITC)-conjugated anti-
human CD34 (BD, Franklin Lakes, NJ USA) by incubat-
ing for 30 min at 4°C according to the manufacturer’s
recommendations. Fluorescent isotype matched antibo-
dies IgG1-FITC/IgG1-PE (BD) were used as controls.
The suspension was then incubated with fluorescence-
activated cell sorter (FACS) lysing solution (BD, Franklin
Lakes, NJ USA) for 10 min, according to the manufac-
turer’s instructions. After washing in phosphate buffered
saline (PBS) and fixation in 1% formaldehyde, samples
were analyzed on a FACSCalibur Instrument (BD). The
percentage of double-positive mononuclear cells (CD34
+/VEGFR2
+) was converted to cells per ml of peripheral
blood using the complete blood count (CBC).
Quantitative real-time RT-PCR
To quantify EPC-specific gene expression, peripheral
blood was incubated for 10 minutes with red blood cell
lysing buffer (Sigma, Munich, Germany) and then cen-
trifuged at 16,000 rpm for 20 seconds at 4°C. Total
RNA isolation was performed using Trizol (Invitrogen)
and cDNA was synthesized from each blood sample
with the SuperScript II Reverse Transcriptase kit (Invi-
trogen) according to the manufacturer’s instructions.
Real-time PCR (25-μl reactions) using SYBR® GreenER
qPCR SuperMix Universal S (Invitrogen, USA) was per-
formed in triplicate in the Mx3000p Real Time PCR
System (Stratagene, USA). The following thermal
cycling conditions were used: 10 sec at 95°C followed
by 40 cycles of 15 sec at 95°C, 20 sec at 60°C, and 7 sec
at 72°C. A no-template control (replacing RNA with
water) was used as a negative control. Target gene
expression was determined using the 2
-ΔΔCt method and
normalized using b-actin as an internal control. To
determine PCR amplification efficiency, standard curves
were constructed using different concentrations of tem-
plate cDNA for CD34, VEGFR-2, and b-actin. For all
genes, the correlation coefficient of the standard curves
was 0.98 or higher, and amplification efficiency was
near 1.0.
The primer sequences used for real-time PCR were as
follows: VEGFR2, 5’-CAC CAC TCA AAC GCT GAC
ATG TA-3’ and 5’-GCT CGT TGG CGC ACT CTT-3’;
CD34, 5’-TTG ACA ACA ACG GTA CTG CTA C-3’
and 5’-TGG TGA ACA CTG TGC TGA TTA C-3’;a n d
b-actin, 5’-TCT GGC ACC ACA CCT TCT AC-3’ and
5’-CTC CTT AAT GTC ACG CAC GAT TTC-3’.
Plasma Assays
Blood levels of VEGF and MMP-9 were measured by
enzyme-linked immunosorbent assay (ELISA) kit (R&D
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instructions.
Statistical Analysis
Statistical analyses were performed with Statistical Pack-
age for Social Sciences 13.0 software (SPSS, USA). The
Mann-Whitney U test and Student’s t-test was used to
compare variables between the two groups. Overall sur-
vival analyses were performed using the Kaplan-Meier
method. Overall survival intervals were determined as
t h et i m ep e r i o df r o mi n i t i al diagnosis to the time of
death. Because of skewed distributions, VEGF and
MMP-9 levels are described using median values and
ranges. EPC level and VEGF/MMP-9 levels were com-
pared with the log-rank statistic. Data are expressed as
mean ± standard error (SE). P < 0.05 was considered
statistically significant.
Results
Numbers of EPCs in peripheral blood of ovarian cancer
patients
We determined the number of EPCs (CD34
+/VEGFR2
+
cells) in the peripheral blood with flow cytometry. Fig-
ure 1A shows a representative flow cytometric analysis
from a pre-treatment ovarian cancer patient (circulating
CD34
+/VEGFR2
+ cells, 1.61%). The percentage of dou-
ble-positive cells (CD34
+/VEGFR2
+)w a sc o n v e r t e dt o
cells per ml of peripheral blood using the complete
blood count. The number of EPCs per ml in the periph-
eral blood of pre-treatment and post-treatment ovarian
cancer patients (1260.5 ± 234.2/ml and 659 ± 132.6/ml)
were higher than that of healthy controls (368 ± 34.5/
ml; P <0 . 0 1a n dP < 0.05, respectively). Treatment sig-
nificantly reduced the number of EPCs/ml of peripheral
blood in patients (P < 0.05) (Fig. 1B).
After a median follow-up of 20.2 months, 26 of the 42
patients (62%) were alive and 16 patients (38%) had died
from ovarian cancer. We established the pre-treatment
EPC cutoff values (395, 670, 945, and 1220 per mL of
peripheral blood; i.e., quartile numbers), which were
tested for ability to predict disease outcome. Our results
showed that low pre-treatment EPC levels (< 945/ml)
were associated with longer survival compared with
higher pre-treatment EPC levels (median survival time,
20.4 months, P = 0.012) (Fig. 1C).
Relationship between circulating EPC levels and clinical
behavior of ovarian cancer
Patient characteristics are summarized in Table 1. No
difference in patient age or histologic subtype was
observed between patient groups. The circulating EPCs
levels in the peripheral blood of stage III and IV ovarian
cancer patients (1450 ± 206.5/ml) was significantly
higher than that of stage I and II patients (1023 ±
104.2/ml; P = 0.034). Furthermore, circulating EPCs
levels in post-treatment ovarian cancer patients with lar-
ger residual tumors (≥ 2 cm) were significantly higher
(875 ± 192.6/ml) compared with those of ovarian cancer
patients with residual smaller tumors (523 ± 92.6/ml; P
= 0.029).
We next sought to determine the relationship between
treatment type and EPCs levels. Surgery and chemother-
apy significantly reduced the number of EPCs per ml of
peripheral blood. However, after treatment, EPCs levels
in the 30 patients who underwent surgery (605 ± 147.2/
ml) and EPCs levels in the 12 patients who received
chemotherapy treatment (783.4 ± 162.5/ml) were still
elevated compared with healthy controls (368 ± 34.5/ml;
P = 0.046).
EPC markers in peripheral blood of ovarian cancer
patients determined by real-time RT-PCR
Peripheral blood CD34 and VEGFR2 mRNA levels were
determined by real-time RT-PCR. Levels of CD34 were
not significantly different in pre-treatment ovarian can-
cer patients compared with healthy controls (Fig. 2A),
whereas VEGFR2 expression in pre-treatment ovarian
cancer patients was 61-fold higher compared with
healthy controls (P = 0.013) (Fig. 2B).
Plasma levels of VEGF and MMP-9
We next compared plasma protein levels of VEGF and
MMP-9 in pre-treatment and post-treatment ovarian
cancer patients with those of healthy controls. For pre-
treatment ovarian cancer patients, the median VEGF
and MMP-9 protein concentrations were 609.1 pg/ml
(range, 43.2-1845.2 pg/ml) and 404.3 ng/ml (range, 35.9-
1623.6 ng/ml), respectively. VEGF and MMP-9 were
present at detectable levels in healthy controls, but at
lower concentrations, 64.4 pg/ml (range, 2.3-448.4 pg/
ml) and 21.34 ng/ml (range, 0.8-335.6 pg/ml), respec-
tively (P < 0.01). Treatment significantly reduced plasma
protein levels of VEGF and MMP-9 to 180.5 pg/ml
(range, 22.4-543.6 pg/ml) and 96.8 ng/ml (range, 12.8-
415.9 pg/ml; P < 0.05) (Fig. 3A-B). Plasma concentra-
tions of VEGF and MMP-9 and circulating EPC levels
were correlated in pre-treatment ovarian cancer patients
(P < 0.01, Fig. 3C-D).
Discussion
EPCs are considered bone-marrow derived cells that
migrate into the peripheral blood in response to cyto-
kines such as VEGF [12]. In contrast to the ischemic
condition, the role of circulating EPCs in tumor angio-
genesis and growth is unclear. EPCs possess a high pro-
liferation potential and have been found to be a
potential marker for both neovascularization and
response to antiangiogenic therapies [13]. The role of
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further investigation, especially in regard to their poten-
tial as markers to monitor disease progression or treat-
ment response. However, to the best of our knowledge,
the potential effect of circulating EPCs in the progres-
sion and angiogenesis of ovarian cancer has not been
reported. In the present study, we investigated the
potential utility of circulating EPCs as a marker for
ovarian tumor progression, angiogenesis, and prognosis.
Previous studies demonstrated that EPCs levels in the
peripheral blood of patients with breast cancer [14],
non-small cell lung cancer [9], and lymphoma [15] were
significantly higher compared with healthy volunteers.
Similarly, we observed in the present study that the
number of circulating EPCs was significantly higher in
patients with ovarian cancer compared with healthy sub-
jects. These findings support the results of animal stu-
dies regarding the mobilization and migration of bone
marrow-derived EPCs via blood circulation into tumor
neovasculature. Despite the small number of subjects in
our study, we observed significant correlations between
circulating EPCs levels and tumor stage and residual
tumor size in ovarian cancer patients. This was consis-
tent with a previous study that reported the relationship
between increased EPC levels and more advanced stages
of breast cancer [11].
Figure 1 (A) Representative flow cytometric analysis from a patient with ovarian cancer. Left: flow cytometry gating. Middle: isotype
negative control for flow-cytometry. Right: representative flow cytometric analysis for determining the number of CD34/VEGFR2 double-positive
cells with a value of 1.61%. (B) Comparison of circulating EPC levels in ovarian cancer patients and healthy subjects. Data are expressed as mean
± SE (**P < 0.01, *P < 0.05). (C) Kaplan-Meier overall survival curve of patients with ovarian cancer according to pre-treatment circulating EPCs
numbers (P = 0.012). The cutoff value between low and high pre-treatment EPC levels was set at 945 EPCs/ml of peripheral blood (median
value).
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or chemotherapy treatment and found that both treat-
ments reduced EPC levels, but not to the low level
observed in healthy controls. Similarly, treatment was
associated with a significant reduction in the levels of
circulating EPCs in patients with lung cancer [9]. More
importantly, follow-up revealed a significantly higher
incidence of death from ovarian cancer in patients with
high pre-treatment EPC levels compared with patients
with low EPCs levels. These findings indicate a possible
relationship between more aggressive ovarian cancer
and higher circulating level of EPCs, suggesting that
EPCs play a role in tumor growth and progression,
thereby facilitating angiogenesis and metastasis.
We next attempted to characterize EPCs-specific mar-
kers CD34 and VEGFR2 in the peripheral blood of
patients with ovarian cancer by real-time RT-PCR.
Interestingly, pre-treatment VEGFR2 mRNA expression
was increased in ovarian cancer patients compared with
healthy controls, but no significant alteration was
observed in CD34 mRNA levels. Elevated VEGFR2 levels
may be due to variations in EPCs expression at different
stages of cell development [12]; this surface receptor can
be expressed on mature endothelial cells as well [16].
Accumulating evidence suggests that VEGF induces
EPC mobilization from the bone marrow into circulation
during tumor angiogenesis [17,18]. In the present study,
soluble VEGF was significantly elevated in patients with
ovarian cancer and was significantly reduced by treat-
ment. Furthermore, circulating EPCs levels correlated
with VEGF and MMP-9 plasma levels. However, the clin-
ical relevance of these results is not completely under-
stood. Recent studies reported that MMP-9 is important
for stem and progenitor cell recruitment from the quies-
cent state into a permissive microenvironment following
stress [19]. It is tempting to speculate that ovarian cancer
tumor cells mobilize bone marrow-derived EPCs into cir-
culation via VEGF and MMP-9 signaling; however, addi-
tional studies with larger patient groups are needed to
elucidate these signaling pathways. Furthermore, circulat-
ing levels of VEGF and MMP-9 have been reported to be
strongly associated with angiogenesis and ovarian cancer
prognosis [20-22]. The present study provides additional
evidence for the possible role of EPCs in ovarian cancer
angiogenesis.
This study has some limitations. No unique marker
for EPCs has yet been reported, and functional charac-
terization of the rare putative EPCs population based on
FACS phenotypes will be difficult to realize for a large
dataset. Consensus on the exact nature of EPCs is
needed to create a standardized, generally excepted
methodology for enumeration of circulating EPCs
[23,24]. Therefore, our descriptions of these cells may
not be universally applicable, making comparisons with
Table 1 Clinical characteristics and circulating endothelial
progenitor cells (EPC) levels of ovarian cancer patients
Clinical characteristic Patients (n) EPCs (per ml) P
Age NS
<43 years old 17 1154 ± 93.7
≥43 years old 25 1205 ± 178.5
Residual tumor size 0.029
<2 cm 22 523 ± 92.6
≥2 cm 8 875 ± 192.6
FIGO stage 0.034
I–II 8 1023 ± 104.2
III–IV 34 1450 ± 206.5
Histological subtype NS
Serous 23 1165 ± 254.6
Mucinous 13 1187 ± 223.7
Endometrioid 6 1235 ± 198.4
Therapy NS
Chemotherapy 12 783.4 ± 162.5
Surgery 30 605 ± 147.2
FIGO, Federation of Obstetrics and Gynecology; NS, not significant. Data are
expressed as mean ± SE.
Figure 2 Pre-treatment and post-treatment relative gene
expression levels of (A) CD34 and (B) VEGFR2 were determined
by real-time RT-PCR.* P = 0.013, versus healthy subjects.
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endothelial cells (CECs) and hematopoietic progenitor
cells may comprise part of the CD34
+/VEGFR2
+ cells
assessed in the present study. CECs are increased in the
blood of cancer patients and correlate with tumor
angiogenesis. Thus it is difficult to conclude that EPCs
exclusively participate in ovarian cancer angiogenesis
and growth. We speculate that EPCs induce endothelial
sprouting through angiogenic growth factors, such as
VEGF. With a better understanding of EPCs in the
future, we can approach the role of EPCs in tumor pro-
gression and angiogenesis, and the effects of antiangio-
genic agents in a more precise manner.
Our study demonstrates that EPCs levels are signifi-
cantly increased in the blood of patients with ovarian
cancer and are correlated with cancer stage and resi-
dual tumor size. Furthermore, treatment reduced cir-
culating EPCs levels of patients. Although our data
suggest a participation of EPCs in tumor growth and
angiogenesis in ovarian cancer, it is not clear whether
these cells are essential for this process. Further inves-
tigation is warranted for potential application of EPCs
in monitoring disease progression and antiangiogenic
drug efficacy, or as a target for ovarian cancer
treatment.
Conclusions
In conclusion, we believe that circulating EPCs may
have potential as a biomarker for monitoring tumor
progression and angiogenesis.
Figure 3 Pre-treatment and post-treatment plasma levels of (A) VEGF (pg/ml) and (B) MMP-9 (ng/ml) in patients with ovarian cancer
and healthy controls. (C) Significant correlation was found between plasma VEGF and circulating EPC levels in patients with ovarian cancer (P
= 0.0043, r = 0.883). (D) Significant correlation was found between plasma MMP-9 and circulating EPC levels for patients with ovarian cancer (P =
0.0027, r = 0.865).
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